SGX-523, an orally bioavailable small molecule, specifically binds to c-Met protein, or hepatocyte growth factor receptor (HGFR), preventing binding of hepatocyte growth factor (HGF) and disrupting the MET signaling pathway. This agent has shown exceptional selectivity for the cMET receptor tyrosine kinase over more than 200 protein kinases.SGX-523 may induce cell death in tumor cells expressing c-Met in vitro and in vivo.Currently, one Phase I studies are performed to evaluate the safety, tolerability and pharmacokinetic profile of SGX523.